Another strong quarter for Baxter's specialties
This article was originally published in Clinica
Baxter's third-quarter sales grew 6% to $2,456 million due to another quarter with strong 15% growth in the medical specialties division. With net income up 9%, "Baxter is on track to reach its financial goals for 1995, including earnings growth in the high single digits and operational cash flow of $500 million," says CEO Vernon Loucks.
You may also be interested in...
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.